NOVEL LABS INC
GenericsNOVEL LABS INC is a generic drug manufacturer focused on Infectious Disease, Respiratory, Dermatology.
NOVEL LABS INC's Key Drugs
NOVEL LABS INC's core commercial portfolio centers on AMLODIPINE BESYLATE AND VALSARTAN, MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE, SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, spanning Infectious Disease and Respiratory — its most strategically important drugs approved in the last 15 years.
NOVEL LABS INC's Recent FDA Approvals
NOVEL LABS INC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
NOVEL LABS INC's Therapeutic Areas
NOVEL LABS INC's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Respiratory, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NOVEL LABS INC's Top Competitors
NOVEL LABS INC's closest competitors by therapeutic-area and drug-target overlap include APOTHECON, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NOVEL LABS INC Pipeline Snapshot
Active clinical trials for NOVEL LABS INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • AMLODIPINE BESYLATE AND VALSARTAN leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (3)
Discontinued (2)
Company Info
- First Approval
- 1985-02-15
- Latest
- 2026-06-18
- Applications
- 59